Japan Tobacco (2914) AI Stock Analysis

• Market Cap: ¥10.63T
• Dividend Yield: 3.49%
• Average Volume (3M): 3.98M
• Price to Earnings (P/E): 20.8
• Beta (1Y): 0.50
• Revenue Growth: 10.18%
• EPS Growth: -48.50%
• Country: JP
• Employees: 53,593
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Tobacco
• EPS (TTM): -0.88
• Shares Outstanding: 2,000,000,000
• 10 Day Avg. Volume: 4,011,180
• 30 Day Avg. Volume: 3,977,306
• PEG Ratio: 0.11
• Price to Book (P/B): 2.45
• Price to Sales (P/S): 2.89
• P/FCF Ratio: 27.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥6,283.33
• Price Target Upside: 5.07% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): 357.17
• Revenue Forecast (FY): ¥3.69T

• Rating: 71 Outperform
• Price Target: ¥6,619.00 ▲(10.69% Upside)
• Action: Reiterated Date: 02/18/26
• Date: Action: Reiterated 02/18/26

The score is driven primarily by solid but uneven financial performance (steady revenue growth, positive cash generation, but recent profit/FCF volatility and higher leverage). Technicals are supportive with price above key moving averages and positive momentum. Valuation is balanced (good yield, but a higher P/E), while the earnings call adds a positive lift due to upgraded guidance and higher dividend expectations despite FX and regional risks.

Positive Factors

Tobacco segment organic growth

Sustained volume growth in heated tobacco and RRP products reflects durable consumer adoption and successful premium product launches (Ploom AURA, EVO). Higher RRP penetration supports structurally better mix and recurring revenue, underpinning medium-term revenue and margin resilience.

Strategic M&A expansion (Vector Group)

The Vector Group acquisition expands JT’s U.S. footprint and adds complementary brands and distribution, providing durable revenue diversification and scale. Successful integration that boosts AOP indicates the deal enhances long-term cash generation and market access in a large tobacco market.

Consistent revenue growth and cash generation

A steady top-line trend combined with repeatedly positive operating and free cash flow demonstrates core cash-generating capacity. Even with some volatility, persistent cash generation supports dividends, reinvestment, and strategic actions over the coming 2–6 months and beyond.

Negative Factors

Rising leverage

A step-up in debt reduces financial flexibility and raises interest and refinancing risk over time. Higher leverage can constrain capital allocation, limit capacity for opportunistic M&A or buybacks, and amplify earnings volatility if operating cash flow softens.

Volatile profitability and free cash flow

Inconsistent conversion of revenue to cash and uneven profitability suggest sensitivity to costs, working-capital timing, and one-offs. Persistent volatility complicates planning, raises earnings risk, and can pressure dividends or investment if adverse conditions persist.

Exposure to FX and risky markets

Material exposure to emerging-market volatility and adverse regulatory/tax changes, combined with negative FX impacts, creates structural revenue and margin risk. These factors can depress local pricing power and cash repatriation, limiting durable earnings visibility.

Japan Tobacco Business Overview & Revenue Model

Company Description

Japan Tobacco Inc., a tobacco company, manufactures and sells tobacco products, prescription drugs, and processed foods in Japan and internationally. The company operates through four segments: Domestic Tobacco, International Tobacco, Pharmaceutical, and Processed Food. It offers tobacco products, such as cigarettes, cigars, pipe tobacco, oral tobacco, waterpipe tobacco, kretek, and fine cut products under the Winston, Camel, MEVIUS, and LD brands. The company also provides reduced-risk products, including tobacco-infused vapor and heated tobacco products, E-Vapor products, etc. under the Ploom, Logic, Ploom TECH, Ploom TECH+, and Ploom S brands. In addition, it researches and develops, manufactures, and sells prescription drugs for the therapeutic areas, such as cardiovascular, renal and metabolism, immunology, and neuroscience. Further, the company provides staple food products, such as frozen noodles and okonomiyaki, and frozen and packed cooked rice; ambient processed foods; bakery products; and seasonings, including yeast extracts and oyster sauce. Japan Tobacco Inc. was founded in 1898 and is headquartered in Tokyo, Japan.

How the Company Makes Money

Japan Tobacco generates revenue primarily through the sale of its tobacco products, which include cigarettes and other nicotine products. The domestic tobacco segment contributes significantly to its earnings, driven by strong brand loyalty and market share in Japan. Internationally, JT benefits from its acquisitions and partnerships, expanding its footprint in various markets worldwide. The company also earns revenue from its reduced-risk products, capitalizing on the growing demand for alternatives to traditional smoking. Furthermore, JT has invested in research and development for innovative products, which helps to sustain its market position and attract consumers. Strategic partnerships and alliances with distributors and retailers also play a crucial role in enhancing its sales and distribution capabilities.

Japan Tobacco Financial Statement Overview

Summary

Fundamentals are solid but mixed: revenue has grown steadily and operating/free cash flow stay positive, yet profitability and free cash flow have become more volatile recently. The balance sheet remains equity-supported, but rising debt in 2024–2025 and weaker 2024 returns add risk.

Income Statement

Revenue shows a steady upward trajectory from 2020 to 2025, with growth remaining positive in the most recent year. Profitability has historically been strong (solid gross profit and healthy profit margins in 2021–2023), but earnings power looks more volatile recently: 2024 profitability compressed materially versus 2023, and while 2025 net income rebounded sharply, margin data is not provided for that year. Overall, the income statement reflects resilient top-line growth with some recent inconsistency in profit conversion.

Balance Sheet

The balance sheet is supported by a large equity base and growing asset levels, but leverage has increased recently: total debt rose meaningfully in 2024–2025 versus 2023, and the debt-to-equity level (where provided) moved higher from 2022–2024. Returns on equity were strong in 2021–2023 but weakened in 2024 alongside lower earnings, signaling a dip in efficiency. Overall financial position remains solid, though the recent step-up in debt and softer 2024 returns are notable risks.

Cash Flow

Cash generation is generally solid with consistently positive operating cash flow and free cash flow across all years. However, cash flow momentum has become choppier: free cash flow declined in 2022, recovered in 2023–2024, then fell again in 2025. In the years where it’s available, free cash flow covered a large portion of net income, supporting earnings quality, but operating cash flow relative to net income appears modest in 2023–2024, suggesting some working-capital or timing drag. Overall, cash flow is healthy but less consistent lately.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	3.47T	3.15T	2.84T	2.66T	2.32T
Gross Profit	1.95T	1.64T	1.51T	1.45T	1.26T
EBITDA	966.32B	454.17B	832.83B	829.17B	687.13B
Net Income	510.18B	179.24B	482.29B	442.72B	338.49B
Balance Sheet
Total Assets	8.42T	8.37T	7.28T	6.55T	5.77T
Cash, Cash Equivalents and Short-Term Investments	831.13B	1.08T	1.04T	866.88B	721.73B
Total Debt	1.68T	1.79T	1.20T	1.02T	979.16B
Total Liabilities	4.30T	4.52T	3.37T	2.93T	2.89T
Stockholders Equity	4.09T	3.77T	3.83T	3.54T	2.81T
Cash Flow
Free Cash Flow	370.85B	502.24B	472.15B	402.39B	512.56B
Operating Cash Flow	514.06B	630.01B	567.01B	483.80B	598.91B
Investing Cash Flow	-265.00B	-439.74B	-125.72B	-101.80B	-97.46B
Financing Cash Flow	-475.46B	-94.94B	-270.91B	-306.20B	-353.18B

Japan Tobacco Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5980.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2914, the sentiment is Positive. The current price of 5980 is above the 20-day moving average (MA) of 5972.00, above the 50-day MA of 5794.84, and above the 200-day MA of 4971.73, indicating a bullish trend. The MACD of 62.00 indicates Positive momentum. The RSI at 55.17 is Neutral, neither overbought nor oversold. The STOCH value of 64.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:2914.

Japan Tobacco Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2914	71 Outperform	¥10.63T	20.83	6.23%	3.49%	10.18%	-48.50%
2503	71 Outperform	¥2.20T	14.86	6.93%	3.05%	4.75%	-24.33%
2587	70 Outperform	¥1.52T	17.12	6.97%	2.42%	1.26%	-13.39%
2501	63 Neutral	¥697.71B	35.48	3.63%	0.67%	0.25%	-58.68%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
2531	61 Neutral	¥317.88B	22.95	―	1.92%	5.66%	-25.08%
2502	60 Neutral	¥2.58T	14.71	6.47%	3.23%	0.86%	0.55%

Japan Tobacco Corporate Events

Japan Tobacco Flags Broad Risk Factors at 2025 Investor Meeting

Japan Tobacco used its 2025 investor meeting materials to outline the range of risks and uncertainties that could materially affect its business, financial condition and operating results. The company emphasized that its projections rely on assumptions that may prove inaccurate, and highlighted factors from health concerns and regulation to litigation, FX volatility and natural disasters.

The disclosure underscores the company’s vulnerability to tightening tobacco controls, changing consumer preferences and intensifying competition, as well as the execution risk in diversifying beyond traditional tobacco and expanding overseas. It signals to investors that external shocks such as political instability and catastrophes, alongside raw material costs and tax policy shifts, could significantly impact performance and strategic ambitions.

The most recent analyst rating on (JP:2914) stock is a Buy with a Yen6662.00 price target. To see the full list of analyst forecasts on Japan Tobacco stock, see the JP:2914 Stock Forecast page.

Japan Tobacco Lifts Profit, Tightens Focus on Core Tobacco as Dividends Rise

Japan Tobacco reported a sharp rebound in performance for the year to December 31, 2025, with revenue from continuing operations up 13.4% to ¥3.47 trillion and operating profit surging to ¥867.0 billion after reclassifying its Pharmaceutical Business as discontinued operations. Profit attributable to owners of the parent jumped 184.6% to ¥510.2 billion, lifting return on equity to 13.0% and allowing the board to raise the annual dividend to ¥234 per share, supported by stronger profitability and a more focused business mix.

The group strengthened its balance sheet, with equity attributable to owners rising to ¥4.09 trillion and the equity ratio improving to 48.5%, even as operating cash flow declined and heavy financing outflows reduced year-end cash. A Canadian litigation settlement involving subsidiary JTI-Macdonald and the liquidation of a Sudanese subsidiary prompted specific profit adjustments for dividend calculation, while the company guided for 2026 revenue of ¥3.70 trillion and a further earnings increase, underpinning a planned dividend hike to ¥242 per share and signaling confidence in its core tobacco operations post-pharma exit.

The most recent analyst rating on (JP:2914) stock is a Buy with a Yen6662.00 price target. To see the full list of analyst forecasts on Japan Tobacco stock, see the JP:2914 Stock Forecast page.